Duchenne muscular dystrophy: Five trials to watch [Yahoo! Finance]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Yahoo! Finance
Dystrophy Association (MDA) 2025 meeting, which took place in Dallas, Texas from 16 to 19 March. The sector was also shaken by the death of a patient who was dosed with Sarepta Therapeutic's DMD gene therapy Elevidys (delandistrogene moxeparvovec), after experiencing acute liver failure. Research by GlobalData estimates that across the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan), the market for DMD treatments is expected to rise from sales of $2.3bn in 2023 to $5.2bn by 2033. This is mostly driven by Elevidys and Santhera Pharmaceuticals' Agamree (vamorolone). GlobalData is the parent company of Clinical Trials Arena At the start of 2025, San Diego-based Capricor Therapeutics completed the submission of its Biologic Licence Application (BLA) for its stem cell-based therapy deramiocel (CAP-1002). The therapy is somewhat unique in that it consists of allogeneic cardiosphere-derived cells (CDCs) which have shown some pre-clinical ability to reg
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular DystrophyGlobeNewswire
- Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at UBS Group AG.MarketBeat
- Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at B. Riley.MarketBeat
- Capricor: A Detailed Examination Of Hope-3 [Seeking Alpha]Seeking Alpha
CAPR
Earnings
- 11/10/25 - In-Line
CAPR
Sec Filings
- 12/5/25 - Form 424B5
- 12/5/25 - Form 8-K
- 12/5/25 - Form 424B3
- CAPR's page on the SEC website